Abstract: ABSTRACT SUSTAINED RELEASE COMPOSITION OF ZINC, ORAL AOLID DOSAGE FORM, AND PROCESS FOR PREPARATION THEREOF The present invention is related to the production of Zinc based composition for sustained release of elemental Zinc upon oral administration. The Zinc based pharmaceutical composition includes salts of Zinc in hydrate, monohydrate, dihydrate, or anhydrous form, preferably of zinc citrate or zinc gluconate or zinc sulfate, along with hydrophilic and/or hydrophobic rate controlling polymer. This sustained release oral formulation is capable to release or maintain elemental zinc up to 7 hours in a sustained manner, to overcome various side effects associated with higher concentration of zinc therapy
DESC:Attached ,CLAIMS:Attached
| # | Name | Date |
|---|---|---|
| 1 | 202211011929-STATEMENT OF UNDERTAKING (FORM 3) [04-03-2022(online)].pdf | 2022-03-04 |
| 2 | 202211011929-PROVISIONAL SPECIFICATION [04-03-2022(online)].pdf | 2022-03-04 |
| 3 | 202211011929-FORM 1 [04-03-2022(online)].pdf | 2022-03-04 |
| 4 | 202211011929-FORM-26 [02-06-2022(online)].pdf | 2022-06-02 |
| 5 | 202211011929-GPA-160622.pdf | 2022-06-21 |
| 6 | 202211011929-Correspondence-160622.pdf | 2022-06-21 |
| 7 | 202211011929-Proof of Right [30-08-2022(online)].pdf | 2022-08-30 |
| 8 | 202211011929-RELEVANT DOCUMENTS [20-09-2022(online)].pdf | 2022-09-20 |
| 9 | 202211011929-FORM 13 [20-09-2022(online)].pdf | 2022-09-20 |
| 10 | 202211011929-Others-101022.pdf | 2022-10-28 |
| 11 | 202211011929-Correspondence-101022.pdf | 2022-10-28 |
| 12 | 202211011929-CORRESPONDENCE-OTHERS [06-03-2023(online)].pdf | 2023-03-06 |
| 13 | 202211011929-COMPLETE SPECIFICATION [06-03-2023(online)].pdf | 2023-03-06 |